Related Experiment Video
Updated: Apr 22, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Age-related changes in familial hypertrophic cardiomyopathy phenotype in transgenic mice and humans
Hong-Chang Luo1,2, Iraklis Pozios1, Styliani Vakrou1
1Division of Cardiology, Johns Hopkins University, Baltimore, Maryland, 410-516-8000, USA.
Insights
Transgenic mice with β-myosin heavy chain mutations closely mimic human hypertrophic cardiomyopathy (HCM). This study confirms that the αMHC(403) mouse model accurately reflects disease progression in humans.
Area of Science:
- Cardiology
- Genetics
- Molecular Biology
Background:
- Hypertrophic cardiomyopathy (HCM) is primarily caused by mutations in the β-myosin heavy chain gene.
- The αMHC(403) transgenic mouse model is widely used to investigate HCM mechanisms.
- Skepticism exists regarding the translational relevance of mouse models to human HCM.
Purpose of the Study:
- To compare the morphologic and functional characteristics of disease progression in the αMHC(403) transgenic mouse model and a human family with a β-myosin heavy chain mutation.
- To assess the validity of the αMHC(403) mouse model in recapitulating human HCM.
Main Methods:
- Morphometric, echocardiographic, tissue Doppler, and strain analyses were performed on αMHC(403) transgenic mice at multiple time points.
- Similar assessments were conducted on human patients from a family with a known β-myosin heavy chain mutation, stratified by generation.
- Comparative analysis of aging-related changes in cardiac structure and function was performed between mice and humans.
Main Results:
- In transgenic mice, aging correlated with increased septal and anterior wall thickness and decreased circumferential and longitudinal strain, alongside a reduced E/A ratio.
- Older HCM patients exhibited significantly worse septal thickness, left atrial volume, E/A ratio, E/e' ratio, global LV strain, and LV early diastolic strain rate compared to younger patients.
- Both transgenic mice and human patients demonstrated similar patterns of morphologic and functional deterioration over time.
Conclusions:
- The αMHC(403) transgenic mouse model demonstrates a progression of morphologic and functional abnormalities that closely mirrors that observed in humans with β-myosin heavy chain mutations.
- This study validates the αMHC(403) mouse as a relevant model for studying human hypertrophic cardiomyopathy.
Abstract:
β-myosin heavy chain mutations are the most frequently identified basis for hypertrophic cardiomyopathy (HCM). A transgenic mouse model (αMHC(403)) has been extensively used to study various mechanistic aspects of HCM. There is general skepticism whether mouse and human disease features are similar. Herein we compare morphologic and functional characteristics, and disease evolution, in a transgenic mouse and a single family with a MHC mutation. Ten male αMHC(403) transgenic mice (at t-5 weeks, -12 weeks, and -24 weeks) and 10 HCM patients from the same family with a β-myosin heavy chain mutation were enrolled. Morphometric, conventional echocardiographic, tissue Doppler and strain analytic characteristics of transgenic mice and HCM patients were assessed. Ten male transgenic mice (αMHC(403)) were examined at ages -5 weeks, -12 weeks, and -24 weeks. In the transgenic mice, aging was associated with a significant increase in septal (0.59±0.06 vs. 0.64±0.05 vs. 0.69±0.11 mm, P<0.01) and anterior wall thickness (0.58±0.1 vs. 0.62±0.07 vs. 0.80±0.16 mm, P<0.001), which was coincident with a significant decrease in circumferential strain (-22%±4% vs. -20%±3% vs. -19%±3%, P=0.03), global longitudinal strain (-19%±3% vs. -17%±2% vs. -16%±3%, P=0.001) and E/A ratio (1.9±0.3 vs. 1.7±0.3 vs. 1.4±0.3, P=0.01). The HCM patients were classified into 1st generation (n=6; mean age 53±6 years), and 2nd generation (n=4; mean age 32±8 years). Septal thickness (2.2±0.9 vs. 1.4±0.1 cm, P<0.05), left atrial (LA) volume (62±16 vs. 41±5 mL, P=0.03), E/A ratio (0.77±0.21 vs. 1.1±0.1, P=0.01), E/e' ratio (25±10 vs. 12±2, P=0.03), global left ventricular (LV) strain (-14%±3% vs. -20%±3%, P=0.01) and global LV early diastolic strain rate (0.76±0.17 s(-1) vs. 1.3±0.2 s-1, P=0.01) were significantly worse in the older generation. In β-myosin heavy chain mutations, transgenic mice and humans have similar progression in morphologic and functional abnormalities. The αMHC(403) transgenic mouse model closely recapitulates human disease.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cellular Adaptation II: Hypertrophy

